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It has been nearly a century since Otto Loewi discovered that acetylcholine (ACh) release
from the vagus produces bradycardia and reduced cardiac contractility. It is now known
that parasympathetic control of the heart is mediated by ACh stimulation of Gi/o-coupled
muscarinic M2 receptors, which directly activate G protein-coupled inwardly rectifying
potassium (GIRK) channels via Gβγ resulting in membrane hyperpolarization and inhibition
of action potential (AP) ﬁring. However, expression of M2R–GIRK signaling components in
heterologous systems failed to recapitulate native channel gating kinetics.The missing link
was identiﬁed with the discovery of regulator of G protein signaling (RGS) proteins, which
act as GTPase-activating proteins to accelerate the intrinsic GTPase activity of Gα resulting
in termination of Gα- and Gβγ-mediated signaling to downstream effectors. Studies in mice
expressing an RGS-insensitive Gαi2 mutant (G184S) implicated endogenous RGS proteins
as key regulators of parasympathetic signaling in heart. Recently, two RGS proteins have
been identiﬁed as critical regulators of M2R signaling in heart. RGS6 exhibits a uniquely
robust expression in heart, especially in sinoatrial (SAN) and atrioventricular nodal regions.
Mice lacking RGS6 exhibit increased bradycardia and inhibition of SANAP ﬁring in response
to CCh as well as a loss of rapid activation and deactivation kinetics and current desen-
sitization for ACh-induced GIRK current (IKACh). Similar ﬁndings were observed in mice
lacking RGS4.Thus, dysregulation in RGS protein expression or function may contribute to
pathologies involving aberrant electrical activity in cardiac pacemaker cells.Moreover, RGS6
expression was found to be up-regulated in heart under certain pathological conditions,
including doxorubicin treatment, which is known to cause life-threatening cardiotoxicity
and atrial ﬁbrillation in cancer patients. On the other hand, increased vagal tone may be
cardioprotective in heart failure where acetylcholinesterase inhibitors and vagal stimulation
have been proposed as potential therapeutics. Together, these studies identify RGS pro-
teins, especially RGS6, as new therapeutic targets for diseases such as sick sinus syndrome
or other maladies involving abnormal autonomic control of the heart.
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INTRODUCTION: CARDIAC AUTOMATICITY
Heart rate (HR) and stroke volume are controlled by the oppos-
ing branches of the autonomic nervous system capable of rapidly
Abbreviations: A. α-helix, amphipathic α-helix; AC, adenylate cyclase; ACh, acetyl-
choline; AF, atrial ﬁbrillation; A1R, adenosine A1 receptor; AP, action poten-
tial; β1AR, β1 adrenergic receptor; β2AR, β2-adrenergic receptor; cAMP, cyclic
AMP; Cys.string, cysteine string motif; DEP/DHEX, dishevelled-EGL-10-pleckstrin
homology domain/DEP helical extension,Egl-10, and pleckstrin homology domain;
Dox, Doxorubicin; ESDC, embryonic stem cell derived cardiocytes; GAP, GTPase
accelerating protein; GEF, guanine nucleotide exchange factor; GGL, Gγ subunit-
like domain; GIRK channel, G protein-activated inwardly rectifying potassium
channel; GoLoco, Gαi/o-loco domain; GPCR, G protein-coupled receptor; HCN,
hyperpolarization-activated cyclic nucleotide-gated cation channels; HR, heart rate;
ICa,L, L-type calcium channel current; I f , pacemaker current; IKACh, acetylcholine-
induced GIRK current;MDP,maximumdiastolic potential;MEF,mouse embryonic
ﬁbroblast; M2R, muscarinic M2 receptor; PCR, polymerase chain reaction; PDZ,
PSD-95 Disk-large ZO-1 domain; PDZM, PDZ docking motif; PKA, protein kinase
A; PTB, phosphotyrosine binding domain; RBD,Ras-binding domain; RGS,Regula-
tor of Gprotein signaling; RGS4,Regulator of Gprotein signaling 4; RGS6,Regulator
of G Protein Signaling 6; R7BP,R7 family RGS binding protein; ROS, reactive oxygen
species.
adjusting cardiac output in response to the body’s oxygen demand.
Neurotransmitters released from both sympathetic and parasym-
pathetic nerves activate members of the G protein-coupled recep-
tor (GPCR) family, the largest family of cell surface receptors
comprising over 800 genes (Fredriksson et al., 2003) and estimated
to be the target of one-third of FDA approved andmarketed drugs
(Hopkins and Groom, 2002). In heart, these GPCRs control var-
ious cellular functions including automaticity and contractility
as well as cell growth and survival. Aberrations in these cardiac
GPCR signaling cascades have numerous pathophysiological con-
sequences and represent the major contributors to cardiovascular
diseases (Salazar et al., 2007). Unsurprisingly, drugs designed to
interfere with autonomic control of the heart and vasculature are
used in the treatment of arrhythmias, hypertension, and heart
failure.
The sympathetic division increases cardiac output as a part of
the “ﬁght-or-ﬂight” response under conditions of stress or high
physical activity by both facilitating action potential (AP) initia-
tion and conduction in the sinoatrial (SAN) and atrioventricular
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nodes (AVN) and increasing cardiac muscle contractility in the
atrium and ventricles. These end results are primarily achieved
by catecholamine-mediated activation of G protein-coupled β1
adrenergic receptors (β1AR) expressed in nodal cells and cardiac
myocytes.Activated β1ARs act as guanine nucleotide exchange fac-
tors (GEFs) promoting the exchange of GDP forGTP-bound to the
αs subunit of the heterotrimericGprotein complex.GTP-Gαs then
stimulates adenylate cyclase-mediated production of the second
messenger cyclic AMP (cAMP), activation of cAMP-dependent
protein kinases, and facilitation of the pacemaker current (I f) in
nodal cells and an increase in L-type calcium channel current
(ICa,L) via channelmodiﬁcation in atrial and ventricularmyocytes
and the SA/AV nodes.
RestingHR in humans is, however, primarily determined by the
parasympathetic divisiondue to greater vagal dischargeunder rest-
ing conditions compared to electrical activity from sympathetic
efferents. Acetylcholine (ACh) released from the vagus nerve,
the primary conduit for efferent parasympathetic nerve activ-
ity, stimulates Gαi/o-coupled muscarinic M2 receptors (M2Rs),
which inﬂuencemembrane excitability both through inhibition of
cAMP production in direct opposition to β1AR signaling as well
as through direct Gβγ-mediated activation of G protein-coupled
inwardly rectifying potassium (GIRK) channels. GIRK channels
represent the primary determinants of ACh-activated potassium
current (IKACh) promoting potassium efﬂux, membrane hyper-
polarization, and inhibition of AP ﬁring in the pacemaker and
electrically conducting portions of the heart (Mark and Herl-
itze, 2000). Studies in mice lacking GIRK4, the cardiac speciﬁc
GIRK channel subunit, revealed that approximately 50% of the
bradycardic response to ACh is mediated by GIRK channel acti-
vation (Wickman et al., 1998). Under normal physiological con-
ditions the vagal nerve is activated by numerous reﬂex control
pathways involving arterial baroreceptors,peripheral chemorecep-
tors, trigeminal receptors, and cardiopulmonary receptors with
vagal afferents designed to sense changes in blood pressure and
oxygenation and stimulate compensatory alterations in HR.
The magnitude and duration of GPCR effector responses is
limited by members of the regulator of G protein signaling (RGS)
family of proteins, which act as GTPase accelerating proteins
(GAPs) for Gα. By stabilizing the transition state of Gα in GTP
hydrolysis, RGS proteins accelerate their intrinsic GTPase activity
to facilitate termination of both Gα- and Gβγ-mediated cellu-
lar signaling (Figure 1). Twenty canonical RGS proteins, divided
into four subfamilies based on sequence homology and the pres-
ence and nature of additional non-RGS domains, act as functional
GAPs for Gαi/o, Gαq/11, or both (Table 1). Many of these proteins
are detectable at the mRNA level in SAN, AVN, atria, or ventri-
cles (Table 1), but lack of speciﬁc antibodies with corresponding
genetic knockout controls hasmade detection of endogenous RGS
proteins difﬁcult in vivo,making investigations into thephysiologi-
cal signiﬁcance of RGSproteins in theheart evenmore challenging.
In fact, only RGS2, 3, 4, 5, and 6 have been detected at the pro-
tein level in heart (Table 1). Furthermore, physiological functions
have only been attributed to a handful of RGS proteins in the heart
and vasculature. Among these, RGS2 is a key regulator of vascu-
lar smooth muscle cell contractility and control of blood pressure
(Heximer et al., 2003; Tang et al., 2003) and both RGS2 and RGS5
FIGURE 1 | Canonical Regulation of GPCR signaling by RGS proteins.
Agonist binding to G protein-coupled receptors (GPCRs) induces a
conformational change that facilitates the exchange of GDP for GTP on the
α subunit of the heterotrimeric complex. Both GTP-bound Gα in the active
form and the released Gβγ dimer can then go on to stimulate a number of
downstream effectors. RGS proteins are GTPase accelerating proteins
(GAPs) for Gα, which function to terminate signaling through GPCRs by
accelerating the intrinsic GTPase activity of Gα and promoting re-association
of the heterotrimeric complex with the receptor at the cell membrane.
have been implicated as key inhibitors of cardiac hypertrophy and
ﬁbrosis in response to pressure overload (Takimoto et al., 2009; Li
et al., 2010; Zhang et al., 2011).
Two RGS proteins, RGS6 and RGS4, have recently been iden-
tiﬁed as critical negative regulators of M2R signaling in heart,
functioning to set the parasympathetic “tone” by acting as the
brake on vagal stimulation of the heart (Figures 2 and 3). It
remains unclear, however, whether RGS6 and RGS4 are redundant
inactivators of cardiacM2R signaling or if they cooperate to ensure
proper parasympathetic control of HRby regulating distinct chan-
nel,GPCR, or G protein populations or by functioning in different
cardiac cells.Nevertheless,dysregulation in the expressionof either
RGS6 or RGS4 could contribute to the loss of vagal tone observed
in cardiovascular diseases. Complete and comprehensive under-
standing of the role of RGS proteins in regulating parasympathetic
stimulation of the heart could lead to the development of novel
treatment strategies for cardiac pathologies involving arrhythmias
and conduction defects that result from unchecked parasympa-
thetic signaling. Among these are pathological AV block, sick sinus
syndrome, and arrhythmias (Fu et al., 2007). Considering the car-
dioprotective effect of increased vagal tone, these RGS proteins are
also being considered as viable druggable targets in the treatment
of heart failure and doxorubicin-induced cardiotoxicity.
THE REQUIREMENT FOR RGS PROTEINS
Prior to the discovery of RGS proteins in 1995 (Dohlman and
Thorner, 1997; Berman andGilman, 1998; Ross andWilkie, 2000),
the model of M2R signaling in cardiac myocytes remained incom-
plete as cardiac speciﬁc GIRK channels expressed in CHO cells
exhibited deactivation kinetics up to 40 times slower than those
observed in native tissues (Doupnik et al., 1997). These results
suggested that an additional component required for normal inac-
tivation of these channels followingM2R stimulationwasmissing.
Expression of several members of the RGS protein family (includ-
ing RGS4) along with GIRK channels and M2Rs restored the
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Table 1 | Canonical RGS protein structure, GAP activity, and expression in cardiac tissue.
Family RGS protein Non-RGS
domains
GAP specificity Cardiac expression (mRNA) Protein Reference
Ventricles Atria
Tissue VM Tissue AM
RZ/A RGS17/RGSZ2 Cys. String Gαi/o Gαq/11, Gαz − + ++ ++ UK Doupnik et al. (2001), Mao
et al. (2004), Zhang andMende
(2011)
RGS19/GAIP Cys. String and
A. α-helix
Gαi/o Gαq/11, Gαz − ++ ++ ++ UK De Vries et al. (1995), Huang
et al. (1997), Doupnik et al.
(2001), Zhang and Mende
(2011)
RGS20/RGSZ1 Cys. String Gαz Gαi/o + + − − UK Glick et al. (1998), Wang et al.
(1998)
R4/B RGS1 A. α-helix Gαi/o and Gαq/11 + ++ − − UK Watson et al. (1996),
Kardestuncer et al. (1998),
Mittmann et al. (2002), Ladds
et al. (2007)
RGS2 A. α-helix Gαq/11 Gαi/o ++ ++ ++ ++ Atrial and
ventricular
myocytes,
ventricles
Heximer et al. (1999), Doupnik
et al. (2001), Mittmann et al.
(2001), Mittmann et al. (2002),
Anger et al. (2004), Hao et al.
(2006)
RGS3 A. α-helix Gαi/o and Gαq/11 ++ ++ ++ ++ Atrial myocytes,
ventricles
Kardestuncer et al. (1998),
Scheschonka et al. (2000),
Doupnik et al. (2001),
Mittmann et al. (2001),
Mittmann et al. (2002), Anger
et al. (2004), Ladds et al.
(2007)
RGS4 A. α-helix Gαi/o and Gαq/11 ++ + ++ ++ SAN, atria Huang et al. (1997),
Kardestuncer et al. (1998),
Doupnik et al. (2001), Cifelli
et al. (2008), Posokhova et al.
(2010), Yang et al. (2010)
RGS5 A. α-helix Gαi/o and Gαq/11 ++ ++ ++ − Ventricular
myocytes,atria,
ventricles
Kardestuncer et al. (1998),
Mittmann et al. (2002), Anger
et al. (2004), Jean-Baptiste
et al. (2005), Chakir et al. (2011)
RGS8 A. α-helix Gαi/o and Gαq/11 − + − − UK Zhong et al. (2003), Zhang and
Mende (2011)
RGS13 A. α-helix Gαi/o and Gαq/11 − − − − UK Johnson and Druey (2002)
RGS16 A. α-helix Gαi/o and Gαq/11 ++ ++ ++ − UK Chen et al. (1997), Chen et al.
(2001), Anger et al. (2004),
Zhang and Mende (2011)
RGS18 A. α-helix Gαi/o and Gαq/11 + + ++ − UK Park et al. (2001), Zhang and
Mende (2011)
RGS21 None Unknown UK UK UK UK UK Von Buchholtz et al. (2004)
R7/C RGS6 GGL and DEP Gαi/o ++ ++ ++ ++ SAN/AVN, atria,
ventricles
Kardestuncer et al. (1998),
Doupnik et al. (2001), Hooks
et al. (2003), Posokhova et al.
(2010), Yang et al. (2010)
(Continued)
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Table 1 | Continued
Family RGS protein Non-RGS
domains
GAP specificity Cardiac expression (mRNA) Protein Reference
Ventricles Atria
Tissue VM Tissue AM
RGS7 GGL and DEP Gαi/o − ++ − − UK Kardestuncer et al. (1998),
Hooks et al. (2003), Zhang and
Mende (2011)
RGS9 GGL and DEP Gαi/o + + − − UK Kardestuncer et al. (1998),
Mittmann et al. (2002), Hooks
et al. (2003)
RGS11 GGL and DEP Gαi/o + − − − UK Snowet al. (1998b), Hooks et al.
(2003)
R12/D RGS10 None Gαi/o and Gαq/11 ++ + ++ ++ Atrial myocytes Tu et al. (1999), Doupnik et al.
(2001), Bender et al. (2008),
Zhang and Mende (2011)
RGS12 PDZ, PTB,
RBD, GoLoco,
and PDZ M
Gαi/o ++ ++ ++ − UK Kardestuncer et al. (1998),
Snow et al. (1998a), Mittmann
et al. (2002), Zhang and Mende
(2011)
RGS14 RBD and
GoLoco
Gαi/o −/+ + − − UK Snow et al. (1997),
Kardestuncer et al. (1998),
Cho et al. (2000), Mittmann
et al. (2002), Zhang and Mende
(2011)
References are listed for RGS proteins exhibiting detectable (+) or strong (++) mRNA expression in heart via northern blot or qPCR. (−) Indicates lack of RGS
protein expression (mRNA) in cardiac tissue (Kardestuncer et al., 1998; Doupnik et al., 2001; Mittmann et al., 2002; Zhang and Mende, 2011) and (UK) indicates that
expression of this RGS isoform is unknown. Tissues or cells where RGS protein expression is detectable by western blot or immunohistochemistry are indicated.
The following additional abbreviations are used: A. α-helix, amphipathic α-helix; AM, atrial myocytes; VM, ventricular myocytes; GGL, Gγ subunit-like domain; DEP,
dishevelled-EGL-10-pleckstrin homology domain; RBD, Ras-binding domain; GoLoco, Gαi/o-loco domain; PDZ, PSD-95 disk-large ZO-1 domain; PDZ M, PDZ docking
motif; PTB, phosphotyrosine binding domain; Cys. String, cysteine string motif.
activation and deactivation kinetics of heterologously expressed
GIRK channels to those observed in native atrial cells (Doupnik
et al., 1997). These ﬁndings demonstrated the essential role of RGS
proteins in regulatingM2R signaling,but failed to identifywhether
this added regulation was required in vivo.
One major challenge to investigating RGS protein function in
living animals is the potential for functional redundancy and com-
pensatory changes in RGS protein expression resulting from loss
of a single protein. To circumvent this issue, a series of trans-
genic mice were developed that express knock-in alleles of RGS-
insensitive Gαmutants. In place of the endogenous protein, these
mice instead express Gαwith a point mutation (G184S in Gαi2) in
the switch I region that blocks the interaction with RGS proteins
necessary for GTPase activation (Lan et al., 1998) without affect-
ing the intrinsic GTPase activity of Gα or its ability to bind Gβγ,
GPCRs, and effectors (Fu et al., 2004). Thus, this mouse model
can be used to evaluate the net regulatory actions of RGS proteins
on various GPCR signaling pathways in vivo.
Using embryonic stem cell derived cardiocytes (ESDCs)
expressing knock-in RGS-insensitive alleles of Gαi2 and Gαo,
endogenous RGS proteins were identiﬁed as key negative
regulators of the agonist-induced negative chronotropic responses
to stimulation of Gαi/o-coupled M2Rs and Gαo-coupled adeno-
sine A1 receptors (A1R). Enhancement in M2R-mediated brady-
cardia primarily occurred through increased GIRK current while
the decreased HR induced by A1R activation occurred via a GIRK
channel-independent mechanism. Mutant cells of each genotype
also showed impaired β2-adrenergic receptor (β2AR)-mediated
tachycardia. Because this effect was sensitive to pertussis toxin,
an inhibitor of Gαi/o, these results implicated RGS proteins in
regulation of Gαi/o-coupled β2ARs. In vivo, the β2AR can couple
either Gαs or Gαi/o with opposing effects on HR. These results
indicate that endogenous RGS proteins speciﬁcally regulate β2ARs
coupled to Gαi/o such that, under basal conditions, the Gαs depen-
dent, non-RGS regulated effect dominates (Fu et al., 2006). Thus
far, only the Gαi2/M2R-dependent sensitization to ACh in the
RGS-insensitive mice has been conﬁrmed in live animals.
Because loss of RGS protein-mediated regulation of Gαi2
could inﬂuence cardiac automaticity through variousmechanisms
including changes in GPCR signaling in the peripheral vasculature
or central nervous system, it was necessary to conﬁrm that the
enhanced bradycardia observed in this mouse model was due to
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FIGURE 2 | Regulator of G protein signaling-mediated regulation of
cardiac automaticity in the sinoatrial node (SAN). In the SAN, Gs-coupled
β1- or β2-adrenergic receptors (β1/2AR) stimulate adenylate cyclase
(AC)-mediated production of the second messenger cyclic AMP (cAMP),
activation of cAMP-dependent protein kinase (PKA), activation of
hyperpolarization-activated cyclic nucleotide-gated cation (HCN) channels and
L-type calcium channels (primarily Cav1.2), and induction of the pacemaker
current (I f ) and calcium current (ICa,L). The net effect is membrane
depolarization and increased nodal cell excitation. AC is inhibited by
Gαi/o-coupled muscarinic M2 receptors (M2R), and activated M2Rs can also
directly induce G protein-coupled inwardly rectifying potassium channel
(GIRK) current (IKACh) via Gβγ resulting in membrane hyperpolarization and
inhibition of nodal cell ﬁring. β2ARs can also couple to Gαi/o in these cells and
block AC-mediated cAMP production. Adenosine A1 receptors (A1R) also have
a negative chronotropic effect in the SAN via Gαo-dependent inhibition of ICa,L,
though the exact mechanism whereby this occurs remains unclear. RGS4 and
RGS6 both function to inactivate Gαi/o activated by M2Rs and block
subsequent acetylcholine-activated GIRK current (IKACh) in SAN. The speciﬁc
RGS protein(s) regulating A1Rs and Gαi/o-coupled β2AR in this tissue have yet
to be identiﬁed.
FIGURE 3 | Regulator of G protein signaling-mediated regulation of
cardiac automaticity in atrial myocytes. In atrial myocytes, Gs-coupled β1-
or β2-adrenergic receptors (β1/2AR) stimulate adenylate cyclase-mediated
production of the second messenger cyclic AMP (cAMP), activation of
cAMP-dependent protein kinase (PKA), and induction of the calcium current
(ICa,L) through L-type calcium channels (primarily Cav1.2). The net effect is
membrane depolarization, increased cell excitation, and enhanced cardiac
contractility. Adenylate cyclase is inhibited by Gαi/o-coupled muscarinic M2
receptors (M2R), and activated M2Rs can also directly induce G
protein-coupled inwardly rectifying potassium channel (GIRK) current (IKACh) via
Gβγ resulting in membrane hyperpolarization and inhibition of cell ﬁring.
β2ARs can also couple to Gαi/o in these cells and block AC-mediated cAMP
production. Adenosine A1 receptors (A1R) also have a negative chronotropic
effect in atrial myocytes via Gαo-dependent inhibition of ICa,L, though the exact
mechanism whereby this occurs remains unclear. RGS6 functions to
inactivate stimulated M2Rs and block subsequent GIRK current (IKACh) in atrial
myocytes. The speciﬁc RGS protein(s) regulating A1Rs and Gαi/o-coupled β2AR
in this tissue have yet to be identiﬁed.
intrinsic alterations in cardiac pacemaker activity. In a follow up
study, enhanced M2R-mediated bradycardia and AV block were
observed in isolated, perfused hearts from mice expressing RGS-
insensitive Gαi2 both under basal conditions and in the presence
of isoproterenol, a non-speciﬁc β-adrenergic receptor agonist used
to mimic sympathetic input. Studies in these mice revealed no
genotype-dependent differences in adenosine-stimulated brady-
cardia consistent with the previously demonstrated preferential
coupling of A1R to Gαo (Fu et al., 2007). While these studies
did ﬁrmly establish the necessity of RGS proteins in controlling
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HR downstream of M2R/Gαi2 stimulation, it failed to determine
which of the numerous RGS proteins present in heart (Table 1)
are responsible for this activity.
SPECIFIC RGS PROTEINS INVOLVED: RGS4 VS. RGS6
RGS4
RGS4 is a member of the R4 subfamily of RGS proteins, which
contain only short N- and C-terminal protein sequences in addi-
tion to their conserved RGS domain. These proteins act as non-
discriminatory GAPs for both Gαi/o and Gαq/11 (Table 1). RGS4
mRNA is enriched in the heart, but there is little to no detectable
RGS4 protein expression (Posokhova et al., 2010;Yang et al., 2010).
The lack of correlation between RGS4 mRNA and protein levels
observed (Xie et al., 2009)may be due to a destabilizingN-terminal
cysteine residue whose arginylation targets RGS4 for degradation
through the ubiquitin-dependent N-end rule pathway (Davydov
and Varshavsky, 2000; Lee et al., 2005). Using an RGS4 knockout
mouse expressing LacZ behind the endogenous RGS4 promoter,
selective enrichment of RGS4mRNA in SANwas observed. This is
an indirect means to measure RGS4 protein localization and may
not reﬂect endogenous RGS4 levels due to differences in protein
regulation (e.g., by the N-end rule pathway) between RGS4 and
the exogenously expressed LacZ.
Though RGS4-null animals exhibited no difference in basal
HR compared to their wild-type counterparts, these mice show
enhanced bradycardia in response to systemic administration
of the M2R agonist carbachol (CCh). In anesthetized animals,
whereparasympathetic tone is increased,RGS4-nullmicedid show
reduced basal HR. These results are consistent with the fact that
sympathetic drive dominates in conscious rodents as opposed to
the greater parasympathetic stimulation of heart under basal con-
ditions observed in humans. Knockout animals also displayed a
larger change in HR upon administration of atropine, a M2R
antagonist, suggesting these mice exhibit increased vagal tone.
These results were replicated in isolated perfused hearts indict-
ing that the enhanced bradycardia resulting from RGS4 loss is
due to intrinsic alterations in cardiac automaticity (Cifelli et al.,
2008).
SAN cells isolated from RGS4-deﬁcient animals also showed
increased sensitivity to CCh-induced inhibition of AP ﬁring and
changes in maximum diastolic potential (MDP). The correlation
between inhibition of AP ﬁring and MDP implicated enhanced
GIRK current as a possible determinant of the enhancedM2R sig-
naling RGS4-null cells. Sinoatrial myocytes isolated from RGS4
knockout mice also exhibited a loss of rapid M2R-activated GIRK
current activation and deactivation kinetics as well as a loss
of current desensitization with no difference in the magnitude
or dose-dependency of the response (Cifelli et al., 2008). The
increased time course of receptor deactivation and desensitization
are consistent with a model whereby RGS4, acting as a GAP for
Gαi/o-coupled M2Rs, functions to inactivate Gβγ-induced IKACh.
Indeed, it was previously established that endogenous RGS pro-
teins are required for proper activation and deactivation kinetics
of agonist-induced GIRK currents (Lambert et al., 2010). RGS4
was shown to mediate these effects in the SAN, but RGS4 mRNA
was not detected in atrial and ventricular cardiomyocytes indicat-
ing lack of RGS4 involvement in M2R signaling in these cell types
(Cifelli et al., 2008). RGS4 appears to also mediate agonist and
voltage-dependent GIRK channel relaxation (Fujita et al., 2000;
Inanobe et al., 2001; Ishii et al., 2001), a process involving relief of
channel pore blockade by intracellular cations and polyamines at
hyperpolarizing potentials and increasing agonist concentration.
As these experiments were performed in heterologous expression
systems or isolated cells, the in vivo signiﬁcance of this latter
effect remains unclear. Nevertheless, the phenotype of enhanced
parasympathetic tone in mice expressing RGS-insensitive Gα
mutants may be due, in part, to loss of RGS4-mediated regulation
of M2Rs in the SAN.
RGS6
RGS6 is a member of the R7 subfamily of RGS proteins charac-
terized by a distinct three domain structure. The conserved RGS
domain confers their GAP activity directed speciﬁcally toward
Gαi/o subunits while the Disheveled-EGL-10-Pleckstrin (DEP)
homology domain and Gγ subunit-like (GGL) domain facilitate
binding of R7 family members to two accessory proteins: R7 fam-
ily binding protein (R7BP), required for membrane targeting, and
Gβ5, an atypical G protein required for R7 family protein stabil-
ity, respectively (Posner et al., 1999; Anderson et al., 2009). Unlike
RGS4, RGS6 expression is detectable at appreciable levels in the
SAN, AVN, atria, and ventricles of mouse hearts via PCR, western
blot, and immunohistochemical staining (Posokhova et al., 2010;
Yang et al., 2010). RGS6 is also highly enriched in the SAN and
AVNalongwith cardiacGIRK channel subunitGIRK1 (Posokhova
et al., 2010; Yang et al., 2010). Similar to the phenotype observed
in RGS4-deﬁcient mice, loss of RGS6 was associated with exagger-
ated bradycardia in response toCCh in conscious and anesthetized
mice and isolated perfused hearts (Yang et al., 2010). Isolated
perfused hearts from RGS6−/− mice also exhibited signiﬁcant
CCh-induced AV block as evidenced by dramatic prolongation
of the PR interval on electrocardiogram tracings.
Consistent with this phenotype of enhanced parasympathetic
stimulation of heart, CCh-induced inhibition of spontaneous
AP ﬁring was exaggerated in SAN pacemaker cells isolated from
RGS6−/− animals (Yang et al., 2010). LikeRGS4,RGS6 also appears
to be required for CCh-induced GIRK channel gating kinetics. In
atrial myocytes from wild-type mice, application of CCh elicited
rapid IKACh that showed signiﬁcant desensitization over time, fol-
lowed by rapid deactivation upon removal of agonist. Conversely,
cells isolated fromRGS6−/− mice exhibited a signiﬁcant reduction
in the time course of activation and deactivation, as well as the
extent of IKACh desensitization (Posokhova et al., 2010; Yang et al.,
2010). The observation that RGS6 is required for desensitization
and rapid activation and deactivation of IKACh in atrial myocytes
and SAN cells is consistent with its role as a GAP for Gi/o. Indeed,
such defects in GIRK desensitization and deactivation in RGS6-
deﬁcient atrial cells likely underlie the exaggerated bradycardia
response to CCh in RGS6−/− mice and isolated hearts. Therefore,
like RGS4, RGS6 is also essential for modulation of M2R signaling
in heart and loss of either protein recapitulates the phenotype of
enhanced parasympathetic tone observed inmice expressing RGS-
insensitive Gαi2. The phenotypes of the various mouse models
used to evaluate the role of RGSproteins inmodulating autonomic
control of heart are summarized in Table 2.
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Table 2 | Mouse models implicating RGS proteins as key modulators of cardiac automaticity and their associated phenotypes.
Mouse model Cell/tissue type Phenotype Reference
RGS-insensitive Gαo (G184S) ESDCs Enhanced negative chronotropic response to
A1R and M2R stimulation; impaired
β2AR-mediated tachycardia
Fu et al. (2006)
RGS-insensitive Gαi2 (G184S) ESDCs Enhanced negative chronotropic response to
A1R and M2R stimulation
Fu et al. (2006)
Isolated, perfused hearts Enhanced M2R (not A1R)-mediated
bradycardia and AV block; prolonged basal AV
conduction
Fu et al. (2007)
Intact animal Enhanced CCh-induced bradycardia and AV
block
Fu et al. (2007)
RGS4 knockout SAN cells Increased sensitivity to CCh-induced
inhibition of AP ﬁring and changes in MDP;
loss of rapid IKACh activation and deactivation
kinetics; and current desensitization
Cifelli et al. (2008)
Isolated, perfused hearts Enhanced M2R-dependent bradycardia Cifelli et al. (2008)
Intact animal Enhanced M2R-mediated bradycardia;
increased Atropine-dependent positive
chronotropy (vagal tone); decreased basal
heart rate (anesthetized animals)
Cifelli et al. (2008)
RGS6 knockout SAN cells Enhanced M2R-mediated inhibition of AP
ﬁring; loss of rapid IKACh deactivation kinetics
Yang et al. (2010), Posokhova et al. (2010)
Atrial myocytes Loss of rapid IKACh activation and deactivation
kinetics and current desensitization
Yang et al. (2010), Posokhova et al. (2010)
Isolated, perfused hearts Enhanced CCh-induced bradycardia and AV
block
Yang et al. (2010)
Intact animal Enhanced CCh-induced bradycardia; mild
resting bradycardia; greater positive
chronotropic effect in response to atropine
Yang et al. (2010), Posokhova et al. (2010)
Gβ5 knockout Atrial myocytes Loss of rapid IKACh deactivation kinetics Posokhova et al. (2010)
RGS2 knockout Intact animal Increased sensitivity to AF and tachycardia
via enhanced muscarinic M3 receptor
signaling
Tuomi et al. (2010)
FUTURE PERSPECTIVES
RGS4, RGS6, OR BOTH?
That fact that both RGS4 and RGS6 knockout animals exhibit
similar phenotypes of enhanced M2R signaling imply that, while
each of these proteins may function in a similar signaling cascade,
they fail to completely compensate for each other’s loss. A num-
ber of hypotheses can be posed to explain these observations. It
is possible that RGS4 and RGS6 regulate distinct receptor sub-
populations, act as GAPs for different G proteins (e.g., Gαi vs.
Gαo), or function to regulate M2Rs in separate cell types. Indeed,
RGS6 is known to bindGαo with higher afﬁnity thanGαi isoforms
in vitro (Hooks et al., 2003) implying it may selectively regulate
M2Rs coupled to Gαo. The observed lack of RGS4 expression out-
side of the SAN implies that RGS6 may be the primary negative
regulator of M2R-mediated GIRK channel activation in AVN and
extra-nodal tissues. In transfected cells expressing exogenous pro-
teins, RGS4 appears to form a complex with the M2R and GIRK
channel subunit GIRK1, though this interaction has not been con-
ﬁrmed in vivo (Jaen and Doupnik, 2006). Conversely, RGS6 fails
to directly bind GIRK1 in vitro or in vivo (Posokhova et al., 2010;
Yang et al., 2010), but does interact with GIRK4 in a heterolo-
gous expression system (Posokhova et al., 2010). These results
suggest RGS4 and RGS6 may selectively regulate distinct GIRK
channel subunits in heart, but the physiological signiﬁcance of
these observations remains unclear. Clearly, the generation of dou-
ble knockout mice is required to facilitate investigations into the
redundant, additive, or synergistic function of RGS4 and RGS6 in
regulating parasympathetic stimulation of heart.
Many of the other RGS proteins expressed at themRNA level in
heart are capable GAPs for Gαi/o (Table 1) and their role in regu-
lating cardiac automaticity remains unknown. A few RGS proteins
are emerging as potential additional players in the regulation of
cardiac automaticity. For example, the enhanced susceptibility to
atrial ﬁbrillation (AF) in RGS2−/− mice suggests involvement of
additional RGS players in heart, though RGS2 is a selective GAP
for Gαq/11 (Heximer et al., 1999) and likely mediates these effects
by regulating Gαq-coupledmuscarinicM3 receptors (Tuomi et al.,
2010). There is also evidence for crosstalk between β1AR signaling
and M2R signaling in heart as isoproterenol, a β-adrenoreceptor
agonist, induces a slowing of IKACh deactivation kinetics, a process
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abolished by knockdown of RGS10 in isolated atrial myocytes
(Bender et al., 2008). These results implicate RGS10 as a down-
stream target of the β1AR in heart and suggest RGS10 might also
function to regulate M2R signaling, though this effect has yet to
be conﬁrmed in vivo. Delineation of the distinct functions of each
of the RGS proteins in controlling cardiac automaticity is essen-
tial to the design and utilization of targeted therapeutics aimed at
modulating RGS protein function in heart. GPCR signaling path-
ways involved in cardiac automaticity and known to be regulated
by endogenous RGS proteins in the SAN and atrial myocytes are
summarized in Figures 2 and 3, respectively.
RGS PROTEIN REGULATION IN HEART
RGS4
Investigations into regulatory mechanisms controlling RGS4 and
RGS6 activity in heart might further elucidate the importance
of RGS4 and RGS6 in both physiological and pathophysiological
regulation of parasympathetic stimulation of heart and the iden-
tiﬁcation of novel means to target their activity. In addition to
regulation of RGS4 expression via the N-end rule pathway, addi-
tional post-translational modiﬁcations control RGS4 stability, and
subcellular localization. Palmitoylation of RGS4 appears to protect
the protein from N-end rule-mediated degradation (Wang et al.,
2010), but the signiﬁcance of these two opposing processes in reg-
ulating RGS4 expression and localization in heart remains unclear.
It is possible that inhibition or activation of key enzymes involved
in this proteolytic cascade could allow for increases or decreases in
RGS4 expression, respectively, and might be valid pharmacologic
means to manipulate RGS4 levels and activity. Atrial natriuretic
peptide induces a PKG-dependent RGS4 phosphorylation and
membrane translocation in astrocytes that enhancesRGS4 activity,
but the relevance of this effect in heart has yet to be determined
(Pedram et al., 2000). The calcium sensor calmodulin, involved
in numerous cardiac pathologies (Zhang et al., 2004), has also
been shown to bind directly to RGS4 relieving phosphatidylinosi-
tol 3,4,5-trisphosphate (PIP3)-mediated inhibition of RGS4 GAP
activity (Popov et al., 2000). Such a mechanism might represent
a means to inhibit IKACh in the SAN in order to enhance cellular
excitability and ensure AP generation in response to increases in
intracellular calcium.
RGS6
Gβ5 is an atypical Gβ subunit in that, instead of interacting with
Gγ, Gβ5 interacts exclusively with R7 family RGS proteins includ-
ing RGS6 in vivo (Snow et al., 1999). This interaction is essential
for the stability, expression, and function of R7 RGS proteins as
conﬁrmed by co-expression studies and the discovery that genetic
deletion of Gβ5 in mice resulted in a loss of all R7 family mem-
bers (Posner et al., 1999; Kovoor et al., 2000; Chen et al., 2003).
Conversely, deletion of RGS9, the only R7 RGS protein in pho-
toreceptors, caused a complete loss of Gβ5 (Chen et al., 2003)
indicating a co-stabilization relationship betweenGβ5 andR7RGS
proteins. The almost complete loss of Gβ5 expression observed in
the atria of RGS6−/− mice (Posokhova et al., 2010;Yang et al., 2010)
identiﬁes RGS6 as the predominant R7 RGS protein expressed
in cardiac tissue. R7BP protein expression is not detectable in
heart (Posokhova et al., 2010; Yang et al., 2010), but low levels of
mRNAexpression have been reported in aorta (Drenan et al., 2005;
Martemyanov et al., 2005). Indeed, complex formation between
RGS6 and Gβ5 but not R7BP is detectable in atrial tissue
(Posokhova et al., 2010; Yang et al., 2010). Gβ5 appears to also
be necessary for normal GIRK channel gating kinetics in response
to M2R stimulation as atrial myocytes isolated from Gβ5−/− mice
exhibit a similar loss of current deactivation as that observed in
mice lacking RGS6 (Posokhova et al., 2010). Thus, targeting of Gβ5
expression might represent an alternate means to control RGS6
activity in heart. RGS6 mRNA is also subjected to complex alter-
native splicing in brain yielding 36 distinct isoforms of the protein
(Chatterjee et al., 2003), a number of which are detectable in heart
(Doupnik et al., 2001; Fisher et al., 2008). This variation inﬂu-
ences the ability of the individual isoforms to associate with Gβ5
and R7BP and, as a result, impacts their stability and subcellular
localization. The differential role of the various RGS6 splice forms
in regulation of cardiac GPCRs has not been explored as studies
investigating the function of RGS6 in heart were performed in a
global knockout mouse lacking expression of all RGS6 isoforms.
BEYOND M2R: REGULATION OF GPCR SIGNALING IN HEART
Thus far the speciﬁc RGS proteins (RGS4 and RGS6) involved
in regulating Gαi/o-coupled M2Rs have been identiﬁed. The
enhanced bradycardia in mice lacking either of these RGS pro-
teins appears to be determined, at least in part, by enhanced
M2R-mediated IKACh. Ventricular myocytes isolated from mice
expressing RGS-insensitive Gαi2 also exhibit sensitization to CCh-
induced inhibition of contractility implicating endogenous RGS
proteins as key regulators of this process (Waterson et al., 2011).
Due to its expression in atria and ventricles, RGS6 might also
regulate this inotropic response to M2R activation, though this
effect has not been directly tested. Studies in cells expressing RGS-
insensitive knock-in Gα alleles also implicated endogenous RGS
proteins as key negative regulators of both the Gαo-coupled A1R
and β2AR signaling through Gαi/o. To date, the consequences of
loss of RGS-mediated regulation of cardiacGPCRs on cAMP levels
and PKA-dependent modulation of I f and ICa,L remains unex-
plored. As the cardioprotective effects of β2AR stimulation occur
via Gαi/o-dependent mechanisms (Xiao, 2001; Patterson et al.,
2004), identiﬁcation of the speciﬁc RGS protein(s) responsible for
negative regulation of this signaling cascade might allow for the
development of targeted therapeutics aimed at speciﬁcally enhanc-
ing the protective, Gαi/o-mediated effect without simultaneous
activation of Gαs.
PHYSIOLOGICAL CONSEQUENCES OF INCREASED VAGAL TONE
Both conscious RGS6−/− and anesthetized RGS4-null mice dis-
play mild resting bradycardia and a greater positive chronotropic
response to administration of the muscarinic antagonist atropine
implying these mice exhibit increased vagal tone (Cifelli et al.,
2008; Posokhova et al., 2010). Thus far, enhanced vagal tone in
these knockout mice has only been assessed using muscarinic
cholinergic receptor blockade. Information gleaned from this
method is limited and fails to assess the full physiological signiﬁ-
cance of enhanced vagal tone in these animalmodels. Fluctuations
in parasympathetic nerve activity under resting conditions are
the primary determinant of HR variability and such measures
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provide an additional index of the magnitude of parasympathetic
modulation of HR (Chapleau and Sabharwal, 2011). ECG record-
ings in mice under basal conditions compared to recording upon
administration of autonomic blockers can be used to assess sym-
pathovagal balance, which would be expected to be skewed toward
the parasympathetic division in mice lacking RGS6 or RGS4. The
vagus is activated by multiple reﬂex pathways including the arte-
rial baroreceptors and peripheral chemoreceptors to slow HR in
response to increases in blood pressure or decreased blood oxy-
gen, respectively (Chapleau and Sabharwal, 2011). RGS null mice
may exhibit exaggerated bradycardia upon administration of a
potent vasoconstrictor or under conditions of hypoxia, hypercap-
nia, or acidosis. Such measurements would give a more accurate
approximation of the physiologically relevant regulation of cardiac
M2Rs by RGS proteins without the administration of exogenous
pharmacological agents.
In humans, RGS6 may indeed be essential for proper control
of parasympathetic stimulation of heart as a single nucleotide
polymorphism in the RGS6 gene is associated with deﬁcits in
HR recovery after exercise (Vasan et al., 2007). During periods
of intense physical exercise, the sympathetic nervous system is
activated with a corresponding inhibition of the parasympathetic
division. Upon exercise termination, reactivation of vagal efferents
is required for the rapid, exponential decline in HR (Chapleau
and Sabharwal, 2011). Unsurprisingly,muscarinic receptor block-
ade compromises HR recovery after exercise (Coote and Bothams,
2001). Post-exercise HR recovery is used as a diagnostic and prog-
nostic tool clinically as it has been shown to be predictive of
morbidity and mortality in chronic heart failure and other car-
diovascular diseases with faster recovery, indicative of increased
vagal tone, associated with better health and lower mortality risk
(Thayer and Lane, 2007; Tang et al., 2009). Indeed, shorter HR
recovery is predictive of overall mortality independent of cardio-
vascular risk factors (Cole et al., 1999). Based on its essential role
in regulating M2R signaling in heart, loss of RGS6 and the con-
sequent increased vagal tone may promote faster HR recovery in
mice. Such a result would implicate RGS6 as a novel target for ther-
apeutic intervention in human patients with failing cardiovascular
health.
RGS6 AND RGS4 IN HEART DISEASE
CHRONOTROPIC DISEASES
Given their essential role in regulating parasympathetic activation
in heart, alterations in RGS4 or RGS6 expression might pro-
vide symptomatic relief in patients with cardiac diseases involving
impaired or excessive vagal activity. Amongst these disorders are
sick sinus syndrome andAV block (Fu et al., 2007). Excessive vagal
stimulation leads directly to AV block, an effect that is primar-
ily dependent on increased GIRK current in mice (Drici et al.,
2000; Hardouin et al., 2002) but can also result from inhibition
of ICa,L by maternal auto-antibodies in cases of congenital heart
block in humans (Garcia et al., 1994). Activation of RGS6 or RGS4
activity in heart would be expected to dampen parasympathetic
stimulation and relieve these symptoms.
Atrial ﬁbrillation is also known to lead to sinoatrial nodal dys-
function in humans and rodents (Sparks et al., 1999; Hadian et al.,
2002; Hocini et al., 2003). Often GIRK currents are constitutively
active in human patients with chronic AF (Dobrev et al., 2005)
and a polymorphism in the Gβ3 subunit of the heterotrimeric G
protein complex resulting in reduced GIRK current is linked to
decreased risk of AF in humans (Schreieck et al., 2004). Loss of
M2R-mediated GIRK channel activation in mouse models, either
through genetic ablation of cardiac speciﬁc GIRK channel GIRK4
or reduced membrane targeting of Gβγ, also resulted in reduced
HR variability and risk for AF (Kovoor et al., 2001; Gehrmann
et al., 2002). Clearly the extent of M2R-mediated GIRK current is
a critical determinant of AF risk. Thus, activation of RGS protein-
mediated negative regulation of cardiac IKACh might be a viable
means of treating AF in the clinic.
HEART FAILURE
Heart failure can lead to diseases of the cardiac conduction sys-
tem such as sick sinus syndrome andAVNdysfunction,whichmay
result from both cardiac damage as well as negatively chronotropic
pharmacological interventions including the use of β-blockers and
digoxin (Monfredi et al., 2010). Impairment of the baroreceptor
reﬂex is also associated with increased mortality in heart failure
(Mortara et al., 1997; Schwartz and De Ferrari, 2011). Emerg-
ing evidence suggests that increased parasympathetic tone may
be protective in heart failure. Donepezil, an acetylcholinesterase
inhibitor used to enhance cholinergic signaling in patients with
Alzheimer’s disease, can produce adverse cardiovascular events
involving bradycardia and AV block (Hernandez et al., 2009)
presumably due to enhanced ACh-mediated M2R signaling in
heart. Nevertheless, Donepezil treatment regimens also reduce the
risk for heart failure related mortality in human patients (Sato
et al., 2010), suggesting that under certain pathological conditions,
enhanced parasympathetic stimulation of the heartmay be cardio-
protective. These results have been recapitulated in rodent models
of heart failure following aortocaval shunt placement (Handa et al.,
2009) and during the acute and chronic phases post-myocardial
infarction (Okazaki et al., 2010; Arikawa et al., 2011). The effects
are likely due to increased parasympatheticmodulation of heart as
an increase in HR variability, a common measure of parasympa-
thetic tone, was observed in Donepezil-treated animals (Okazaki
et al., 2010). Similar observations have also been found using vagal
nerve stimulation protocols in humans (Schwartz and De Ferrari,
2009) and rodents (Li et al., 2004).
The exact mechanism underlying the cardioprotective effect
of enhanced vagal tone remains unclear, though it is believed to
involve the anti-apoptotic effects of PI3K/Akt/HIF-1α signaling
through atropine-sensitive muscarinic ACh receptors (Kakinuma
et al., 2005). Such receptors can couple either Gαi/o or Gαq, which
activates or inhibits Akt signaling, respectively, suggesting the
cardioprotective effects of vagal stimulation may occur through
Gαi/o-coupled M2Rs known to be regulated by RGS6 and RGS4
in heart. Thus, the RGS6 and RGS4 knockout mice, both of which
exhibit a phenotype of enhanced parasympathetic tone, would be
expected to be protected from heart failure induced cardiac dam-
age and mortality. Identiﬁcation of the speciﬁc receptor signaling
pathways involved would facilitate investigations into the role of
RGS proteins in modulating these processes and their potential as
therapeutic targets in the treatment of heart failure. Loss of RGS-
mediated regulation of Gαi2 also protects isolated, perfused hearts
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against ischemic injury including reduction in infarct size and
improved recovery of contractile function. Interestingly, inhibi-
tionofmitochondrial and sarcolemmalATP-dependentpotassium
channels and not the PI3K/Akt/GSK-3β and MEK/ERK signaling
cascades blocked the cardioprotective phenotype in these animals.
This study points to an entirely novel, anti-apoptotic pathway reg-
ulated by RGS proteins in the heart (Waterson et al., 2011). Thus,
inhibition of cardiac RGS proteins might represent a viable means
to enhance the protective effects of endogenous GPCR agonists
such as opioids, bradykinin, and adenosine released from the heart
during periods of ischemia (Cohen et al., 2000).
RGS4mRNA and protein levels are up-regulated in the left ven-
tricular myocardium of human patients with dilated and ischemic
cardiomyopathy (Mittmann et al., 2002) and end-stage heart fail-
ure (Owen et al., 2001) suggesting that, despite the absence of its
expression in atria and ventricles under basal conditions, RGS4
might be an important regulator of GPCR signaling in heart
under speciﬁc pathological conditions. Exogenous RGS4 expres-
sion in ventricular myocytes also suppressed endothelin-1 depen-
dent activation of phospholipase C and the resulting increase in
myocyte contractility. This function, if it occurs in vivo, is in direct
opposition to the effects of RGS4 on M2R signaling implying
that RGS4 may have opposing effects on cardiac inotropy and
chronotropy depending on the physiological context (Mittmann
et al., 2002). To complicate matters even more, transgenic over-
expression of RGS4 in murine ventricular cardiomyocytes exac-
erbates heart damage and mortality due to heart failure after
transverse aortic constriction but transiently improved cardiac
hypertrophy (Rogers et al., 1999). RGS4-mediated protection from
cardiac hypertrophy and contractile dysfunctionwas also observed
inmice overexpressingGαq (Rogers et al., 2001). Further investiga-
tion into the effect of RGS4 knockout on heart failure progression
in mouse models might shed some light on these seemingly para-
doxical observations. Indeed, a majority of the studies in mice
were performed in transgenic animals overexpressing exogenous
RGS4. As RGS4 expression is not detectable in appreciable levels in
the myocardium under basal conditions (Posokhova et al., 2010;
Yang et al., 2010), the physiological relevance of these ﬁndings is
questionable. Due to the promiscuous regulation of both Gαi/o
and Gαq/11-dependent signaling pathways by RGS4 and the oft
times opposing functions of these GPCR cascades, RGS6, which
exclusively interacts with Gαi/o, might be a more speciﬁc target to
enhance parasympathetic signaling in heart. Pathological upreg-
ulation of RGS6 in failing myocardium of human patients and
mouse models has yet to be explored.
DOXORUBICIN-INDUCED CARDIOTOXICITY
Doxorubicin (Dox) is an anthracycline that is among the most
effective and widely used chemotherapeutic drugs to treat human
cancers including leukemia, lymphoma, multiple myeloma, and
breast cancer (Carter, 1975). However, the major obstacle restrict-
ing clinical utility of anthracyclines is their dose-dependent, life-
threatening cardiotoxicity (Gianni et al., 2008). Dox induces acute
cardiotoxicity, occurring immediately or weeks after treatment
cessation and commonly presenting as sinus tachycardia that sug-
gests autonomic dysfunction (Bristow et al., 1978; Lipshultz et al.,
2008); and chronic cardiotoxicity, which usually develops in the
ﬁrst year following treatment and presents as left ventricular dys-
function and chronic heart failure (Bristow et al., 1978; Praga et al.,
1979; Singal and Iliskovic, 1998).
The mechanism of Dox-induced cardiotoxicity is not fully
understood. However, Dox-induced production of reactive oxy-
gen species (ROS) has been implicated as critical for subsequent
cardiac myocyte apoptosis and heart damage (Li and Singal, 2000;
Zhou et al., 2001; Pacher et al., 2003). The chemotherapeutic efﬁ-
cacy of Dox relies on its ability to kill cancer cells by activating
the ATM–p53 apoptosis pathways (Evan, 1997; Canman et al.,
1998; Khanna et al., 1998; Bakkenist and Kastan, 2003; Iliakis et al.,
2003), which is also responsible for Dox-induced cardiotoxicity as
inhibition of components of this pathway protects against Dox-
induced heart injury in mice (Liu et al., 2004; Shizukuda et al.,
2005; Yoshida et al., 2009; Zhu et al., 2009). RGS6 plays an essen-
tial role in mediating activation of ATM and p53 induced by Dox
in a ROS-dependent manner (Huang et al., 2011), implicating
RGS6, whose expression is enriched in heart (Yang et al., 2010), as
a key mediator of Dox-induced cardiotoxicity. Consistently, loss
of RGS6 reduces apoptosis of heart cells and consequent heart
damage in Dox-treated mice (Huang et al., 2011).
RGS6 has been shown to be induced by Dox in MEFs and
cancer cells (Huang et al., 2011). As described above, RGS6 plays
a critical role in regulating parasympathetic vagal control in the
heart. Thus, this early induction of RGS6 by Dox may be involved
in Dox-induced acute AF by interfering with the normal gating
kinetics of GIRK current. Evaluation of RGS6 protein levels and
IKACh properties in SAN cells isolated from WT and RGS6
−/−
mice treated with Dox is required to further test this hypothesis.
RGS6 is also required for Dox-induced ROS production. Loss
of RGS6 impairs Dox-induced ROS generation in MEFs (Huang
et al., 2011). It has been recently reported that Dox induces a
ROS- and CaMKII-dependent Ca2+ leakage from sarcoplasmic
reticulum (SR; Sag et al., 2011). Normal heart rhythm is initi-
ated and regulated by oscillatory SR Ca2+ release (Ca2+ clock) in
SAN cells, which by rhythmically activating Na+/Ca2+ exchanger
inward current, prompts membrane ion channels to ﬁre rhythmic
APs (Maltsev and Lakatta, 2007). Therefore, RGS6 may promote
Dox-induced AF by mediating Dox-induced ROS generation and
consequent SR Ca2+ leakage disturbing the normal rhythm of
intracellular Ca2+ clock in SAN cells. Interestingly, the ability of
RGS6 to mediate ROS generation is not dependent on its inter-
action with G proteins (Huang et al., 2011; Maity et al., 2011),
suggesting a unique role of RGS6, but not other RGS proteins, in
controlling Dox-induced autonomic dysfunction. The possibility
that RGS6 induction by Dox might underlie cardiac patholo-
gies resulting from anthracycline chemotherapy is intriguing,
but remains an untested hypothesis requiring veriﬁcation from
multiple laboratories for ﬁnal conﬁrmation.
POTENTIAL AS THERAPEUTIC TARGETS
Due to their role in regulation of GPCR signaling pathways in the
cardiovascular system in both physiological and pathophysiolog-
ical contexts, RGS proteins have emerged as potential therapeutic
targets in the treatment of various heart-related diseases. While
GPCR agonists and antagonists have been used successfully in the
clinic for years, additional therapeutic beneﬁt could be derived
Frontiers in Physiology | Cardiac Electrophysiology April 2012 | Volume 3 | Article 95 | 10
Stewart et al. RGS proteins in cardiac automaticity
from the additive or singular use of compounds designed to
enhance or inhibit RGS protein function. In diseases involving
loss of parasympathetic tone or over-activation of sympathetic
nerves, inhibition, or activation of either RGS4 or RGS6 would be
expected to enhance or block signaling resulting from endogenous
release of vagal ACh and subsequent slowing of HR, respectively.
In the case of pathological upregulation of RGS6 and RGS4 that
occur inDox-induced cardiotoxicity andheart failure, respectively,
RGS protein inhibition might help to mitigate heart damage.
Small-molecule inhibitors of RGS4 have been developed. The
ﬁrst, CCG-4986 binds irreversibly to RGS4 and results in covalent
modiﬁcation and permanent, allosteric inhibition of the protein
making it less than ideal for clinical use and in vivo investigation
intoRGS4 function (Romanet al., 2010).Amore recent compound
has been identiﬁed with similar but reversible effects (Blazer et al.,
2010). It appears that some degree of selectivity can be achieved
despite the similarity in protein sequence between members of
the various RGS protein subfamilies. Targeting regulatory mecha-
nismsmight also represent viablemeans tomanipulate the expres-
sion of speciﬁc RGS proteins. In addition to their clinical use, such
compounds might also have utility in investigating the physiolog-
ical and pathophysiological functions of RGS proteins, singularly,
or for multiple proteins, for which there exists no genetic knock-
out model or those whose loss, alone or in combination, results in
embryonic or post-natal lethality.
CONCLUSION
Pioneering work done in mice expressing RGS-insensitive Gα
alleles identiﬁed RGS proteins as key modulators of cardiac
automaticity. Further advances in transgenic mouse technology
allowed for the identiﬁcation of two speciﬁc RGS proteins (RGS4
and RGS6) responsible for negatively regulating M2R signaling
in pacemaker cells and conducting portions of the heart. Nev-
ertheless, many avenues relating to the physiological function
of endogenous RGS proteins in controlling cardiac automatic-
ity remain unexplored. Of the 10 RGS proteins expressed in the
myocardium, only a handful have been ascribed speciﬁc func-
tions some of which appear functionally redundant. Additional
regulatory mechanisms controlling RGS protein function further
complicates matters but also allows for the opportunity to identify
additional means to manipulate RGS protein expression for some
therapeutic beneﬁt. As dysregulation in autonomic control of the
heart contributes to numerous cardiac pathologies, elucidation
of GPCR signaling cascades controlling automaticity and regu-
lated by endogenous RGS proteins has the potential to facilitate
the identiﬁcation of novel treatments for a number of cardiovas-
cular diseases, which remain the leading cause of death in the
United States and worldwide. Among these are chronotropic dis-
eases including sick sinus syndrome,pathologicalAVblock andAF,
heart failure and ischemic heart injury, and doxorubicin-induced
cardiotoxicity.
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